

## **HEPATOCELLULAR CARCINOMA, LI-RADS, TEMPLATE**

( LI-RADS<sup>®</sup> is Liver Reporting & Data System)

DATE OF EXAMINATION

EXAMINATION TYPE: CT/MRI

SCANNER MODEL, FIELD STRENGTH. USED COILS, USED PULSE SEQUENCES, NUMBER OF DETECTOR ROWS, SLICE THICKNESS

Patient's info: name, date of birth

Specify type and dose of IV contrast administration

Liver:

The liver is [cirrhotic/not cirrhotic].

The background liver parenchyma is [homogeneous/heterogeneous but not nodular/extensively nodular].

Hepatic arterial anatomy:

Portal vein assessment:

Tumor findings:

- Location: segment [I/II/III/IVa/IVb/V/VI/VII/VIII/other (describe)]
- Size: [ ] × [ ] × [ ] [mm/cm]
- Tumor in vein: [no/yes (describe the involved vessels)]
- LR-M features: [none/list all that apply]
- Nonrim arterial phase hyperenhancement: [yes/no]
- Threshold growth: [yes/no/not applicable]
- Nonperipheral washout appearance: [yes/no]
- Enhancing capsule appearance: [yes/no]

Ancillary features:

- Favoring benignity: [none/list all that apply]
- Favoring malignancy: [none/list all that apply]
- Remainder of the abdomen: there is [no] extrahepatic malignancy

February 2022

Conclusion: LI-RADS category: [LR-NC/LR-1/LR-2/LR-3/LR-4/LR-5/LR-TIV/LR-M]

#### Ancillary features favoring malignancy in general, not HCC in particular

- US visibility as discrete nodule
- Subthreshold growth
- Restricted diffusion
- Mild-moderate T2 hyperintensity
- Corona enhancement
- Fat sparing in solid mass
- Iron sparing in solid mass
- Transitional phase hypointensity
- Hepatobiliary phase hypointensity

#### Favoring HCC in particular

- Nonenhancing "capsule"
- Nodule-in-nodule
- Mosaic architecture
- Blood products in mass
- Fat in mass, more than adjacent liver

#### Ancillary features favoring benignity

- Size stability > 2 years
- Size reduction
- Parallels blood pool
- Undistorted vessels
- Iron in mass, more than liver
- Marked T2 hyperintensity
- Hepatobiliary phase isointensity